PGE2 suppression of innate immunity during mucosal bacterial infection

Prostaglandin E2 (PGE2) is an important lipid mediator in inflammatory and immune responses during acute and chronic infections. Upon stimulation by various proinflammatory stimuli such as lipopolysaccharide (LPS), interleukin (IL)-1β, and tumor necrosis factor (TNF)-α, PGE2 synthesis is upregulate...

Full description

Bibliographic Details
Main Authors: Mallory eAgard, Saja eAsakrah, Lisa A Morici
Format: Article
Language:English
Published: Frontiers Media S.A. 2013-08-01
Series:Frontiers in Cellular and Infection Microbiology
Subjects:
Online Access:http://journal.frontiersin.org/Journal/10.3389/fcimb.2013.00045/full
_version_ 1831812459490443264
author Mallory eAgard
Saja eAsakrah
Lisa A Morici
author_facet Mallory eAgard
Saja eAsakrah
Lisa A Morici
author_sort Mallory eAgard
collection DOAJ
description Prostaglandin E2 (PGE2) is an important lipid mediator in inflammatory and immune responses during acute and chronic infections. Upon stimulation by various proinflammatory stimuli such as lipopolysaccharide (LPS), interleukin (IL)-1β, and tumor necrosis factor (TNF)-α, PGE2 synthesis is upregulated by the expression of cyclooxygenases. Biologically active PGE2 is then able to signal through four primary receptors to elicit a response. PGE2 is a critical molecule that regulates the activation, maturation, migration, and cytokine secretion of several immune cells, particularly those involved in innate immunity such as macrophages, neutrophils, natural killer cells, and dendritic cells. Both Gram-negative and Gram-positive bacteria can induce PGE2 synthesis to regulate immune responses during bacterial pathogenesis. This review will focus on PGE2 in innate immunity and how bacterial pathogens influence PGE2 production during enteric and pulmonary infections. The conserved ability of many bacterial pathogens to promote PGE2 responses during infection suggests a common signaling mechanism to deter protective pro-inflammatory immune responses. Inhibition of PGE2 production and signaling during infection may represent a therapeutic alternative to treat bacterial infections. Further study of the immunosuppressive effects of PGE2 on innate immunity will lead to a better understanding of potential therapeutic targets within the PGE2 pathway.
first_indexed 2024-12-22T21:36:54Z
format Article
id doaj.art-81d5d0581b274df79ab1d4689104f617
institution Directory Open Access Journal
issn 2235-2988
language English
last_indexed 2024-12-22T21:36:54Z
publishDate 2013-08-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Cellular and Infection Microbiology
spelling doaj.art-81d5d0581b274df79ab1d4689104f6172022-12-21T18:11:43ZengFrontiers Media S.A.Frontiers in Cellular and Infection Microbiology2235-29882013-08-01310.3389/fcimb.2013.0004555889PGE2 suppression of innate immunity during mucosal bacterial infectionMallory eAgard0Saja eAsakrah1Lisa A Morici2Tulane University School of MedicineTulane University School of MedicineTulane University School of MedicineProstaglandin E2 (PGE2) is an important lipid mediator in inflammatory and immune responses during acute and chronic infections. Upon stimulation by various proinflammatory stimuli such as lipopolysaccharide (LPS), interleukin (IL)-1β, and tumor necrosis factor (TNF)-α, PGE2 synthesis is upregulated by the expression of cyclooxygenases. Biologically active PGE2 is then able to signal through four primary receptors to elicit a response. PGE2 is a critical molecule that regulates the activation, maturation, migration, and cytokine secretion of several immune cells, particularly those involved in innate immunity such as macrophages, neutrophils, natural killer cells, and dendritic cells. Both Gram-negative and Gram-positive bacteria can induce PGE2 synthesis to regulate immune responses during bacterial pathogenesis. This review will focus on PGE2 in innate immunity and how bacterial pathogens influence PGE2 production during enteric and pulmonary infections. The conserved ability of many bacterial pathogens to promote PGE2 responses during infection suggests a common signaling mechanism to deter protective pro-inflammatory immune responses. Inhibition of PGE2 production and signaling during infection may represent a therapeutic alternative to treat bacterial infections. Further study of the immunosuppressive effects of PGE2 on innate immunity will lead to a better understanding of potential therapeutic targets within the PGE2 pathway.http://journal.frontiersin.org/Journal/10.3389/fcimb.2013.00045/fullBacteriaInfectionprostaglandinCOXimmunotherapeuticmucosal
spellingShingle Mallory eAgard
Saja eAsakrah
Lisa A Morici
PGE2 suppression of innate immunity during mucosal bacterial infection
Frontiers in Cellular and Infection Microbiology
Bacteria
Infection
prostaglandin
COX
immunotherapeutic
mucosal
title PGE2 suppression of innate immunity during mucosal bacterial infection
title_full PGE2 suppression of innate immunity during mucosal bacterial infection
title_fullStr PGE2 suppression of innate immunity during mucosal bacterial infection
title_full_unstemmed PGE2 suppression of innate immunity during mucosal bacterial infection
title_short PGE2 suppression of innate immunity during mucosal bacterial infection
title_sort pge2 suppression of innate immunity during mucosal bacterial infection
topic Bacteria
Infection
prostaglandin
COX
immunotherapeutic
mucosal
url http://journal.frontiersin.org/Journal/10.3389/fcimb.2013.00045/full
work_keys_str_mv AT malloryeagard pge2suppressionofinnateimmunityduringmucosalbacterialinfection
AT sajaeasakrah pge2suppressionofinnateimmunityduringmucosalbacterialinfection
AT lisaamorici pge2suppressionofinnateimmunityduringmucosalbacterialinfection